株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

二次性副甲状腺機能亢進症 : パイプライン分析

Secondary Hyperparathyroidism - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 253669
出版日 ページ情報 英文 57 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.53円で換算しております。
Back to Top
二次性副甲状腺機能亢進症 : パイプライン分析 Secondary Hyperparathyroidism - Pipeline Review, H2 2019
出版日: 2019年09月23日 ページ情報: 英文 57 Pages
概要

二次性副甲状腺機能亢進症は、カルシウムレベルの著しい低下から首の副甲状腺が副甲状腺ホルモン(PTH)を過剰に分泌する状態をいい、骨の変形、骨折、関節腫脹、慢性腎不全などの症状があります。治療法には、 カルシウム受容体作動薬およびホルモン補充療法などがあります。

当レポートでは、世界における二次性副甲状腺機能亢進症治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

二次性副甲状腺機能亢進症の概要

治療薬の開発

  • 二次性副甲状腺機能亢進症向けパイプライン製品:概要
  • 二次性副甲状腺機能亢進症向けパイプライン製品:比較分析

二次性副甲状腺機能亢進症:開発中の治療薬:企業別

二次性副甲状腺機能亢進症:パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

二次性副甲状腺機能亢進症:開発中の製品:企業別

二次性副甲状腺機能亢進症:治療薬開発に従事している企業

  • Amgen Inc.
  • Deltanoid Pharmaceuticals Inc.
  • 田辺三菱製薬
  • Nektar Therapeutics
  • OPKO Health, Inc.

二次性副甲状腺機能亢進症:治療薬の評価

  • 単剤治療薬
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • Calcifediol MR
  • Calcimimetic-18
  • CTA-091
  • CTAP-201
  • DP-001
  • Drugs to Inhibit CYP24 for Secondary Hyperparathyroidism, Chronic Kidney 疾患 and Cancer
  • etelcalcetide
  • lunacalcipol
  • MT-4580
  • NKTR-228
  • VS-105
  • VS-110
  • VS-411
    • 製品概要
    • 作用機序
    • R&Dの進捗

最新のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development for Secondary Hyperparathyroidism, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Secondary Hyperparathyroidism - Pipeline by Amgen Inc, H2 2019
  • Secondary Hyperparathyroidism - Pipeline by EA Pharma Co Ltd, H2 2019
  • Secondary Hyperparathyroidism - Pipeline by Lupin Ltd, H2 2019
  • Secondary Hyperparathyroidism - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2019
  • Secondary Hyperparathyroidism - Pipeline by OPKO Health Inc, H2 2019
  • Secondary Hyperparathyroidism - Dormant Projects, H2 2019
  • Secondary Hyperparathyroidism - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Secondary Hyperparathyroidism, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC11390IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Secondary Hyperparathyroidism - Pipeline Review, H2 2019, provides an overview of the Secondary Hyperparathyroidism (Hormonal Disorders) pipeline landscape.

Secondary hyperparathyroidism is occurs when the parathyroid glands in neck produce too much parathyroid hormone (PTH) because calcium levels are too low. Symptoms include bone deformities, broken bones, swollen joints and chronic kidney failure. Treatment includes calcimimetic and hormone replacement therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Secondary Hyperparathyroidism - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Secondary Hyperparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Secondary Hyperparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1, 3 and 2 respectively.

Secondary Hyperparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Secondary Hyperparathyroidism (Hormonal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Secondary Hyperparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Secondary Hyperparathyroidism (Hormonal Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Secondary Hyperparathyroidism (Hormonal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
    • Secondary Hyperparathyroidism - Overview
    • Secondary Hyperparathyroidism - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Secondary Hyperparathyroidism - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Secondary Hyperparathyroidism - Companies Involved in Therapeutics Development
    • Amgen Inc
    • EA Pharma Co Ltd
    • Lupin Ltd
    • Mitsubishi Tanabe Pharma Corp
    • OPKO Health Inc
  • Secondary Hyperparathyroidism - Drug Profiles
    • AJT-240 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • calcifediol ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cinacalcet - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CK-15 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTA-091 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Dendocrin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etelcalcetide hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • evocalcet - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LNP-1892 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VS-105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Secondary Hyperparathyroidism - Dormant Projects
  • Secondary Hyperparathyroidism - Discontinued Products
  • Secondary Hyperparathyroidism - Product Development Milestones
    • Featured News & Press Releases
      • Sep 04, 2018: OPKO initiates RAYALDEE phase 2 trial in dialysis patients
      • Jul 16, 2018: OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Canada
      • May 22, 2018: Kyowa Hakko Kirin Launches ORKEDIA TABLETS (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan
      • Mar 23, 2018: Kyowa Hakko Kirin Receives Approval for ORKEDIA Tablets (Evocalcet) for the Treatment of Secondary Hyperparathyroidism in Patients on Maintenance Dialysis in Japan
      • Nov 06, 2017: Kyowa Hakko Kirin Presented Results of Japan Phase III Clinical Study of Evocalcet at Kidney Week 2017 of the American Society of Nephrology
      • Jun 22, 2017: OPKO Health Announces KDIGO Clinical Practice Guideline Update on CKD-MBD
      • Jun 05, 2017: OPKO Health Provides Commercial Update for RAYALDEE
      • Apr 27, 2017: Kyowa Hakko Kirin Submits Application for Approval of Evocalcet (KHK7580) for Secondary Hyperparathyroidism in Maintenance Dialysis Patients in Japan
      • Feb 15, 2017: Launch of PARSABIV Intravenous Injection for Dialysis, a Calcimimetic Agent, for Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis
      • Feb 07, 2017: OPKO Health Promotes Thomas Nusbickel to Renal Division Chief Commercial Officer
      • Feb 07, 2017: FDA Approves Amgen's Parsabiv (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis
      • Jan 31, 2017: Kyowa Hakko Kirin Announces Top-Line Results of Phase 3 Clinical Study of KHK7580 with Secondary Hyperparathyroidism in Japan
      • Jan 10, 2017: Study Results Published in the Journal of the American Medical Association Show Amgen's Parsabiv (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparathyroidism on Hemodialysis
      • Dec 19, 2016: ONO Receives Manufacturing and Marketing Approval in Japan for PARSABIV, a Calcimimetic Agent, for the Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis
      • Nov 18, 2016: ONO Announces Results from Phase 1/2 and Long- term Clinical Studies of Etelcalcetide Hydrochloride (ONO -5163) in Hemodialysis Patients with Secondary Hyperparathyroidism in Japan at ASN Kidney Week 2016
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top